Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Replicor Inc. logo — 292 million people have chronic hepatitis B. We're developin...

Replicor Inc.

292 million people have chronic hepatitis B. We're developing the cure.

Canada Montreal, Canada 6 employees Biotechnology, Health Care

General Information

Company Name Replicor Inc.
Location Canada Montreal, Canada
Employees 6
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Replicor Inc.. To contact Replicor Inc., visit replicor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Replicor Inc. compare?

A PDF of Replicor Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Replicor Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Replicor Inc.

Replicor Inc. is a Canadian biotechnology company dedicated to developing a cure for chronic hepatitis B (HBV) and delta (HDV) infections. Their innovative nucleic acid polymer (NAP) technology directly targets the immunosuppressive protein (HBsAg) responsible for chronic HBV infection and liver disease. Their lead clinical NAP drug product, REP 2139-Mg, has shown promising results in restoring immune control of HBV infection in 78% of patients and eliminating HDV infection in 74% of patients. What's particularly noteworthy is that these effects persist without any therapy, allowing the liver to heal. Moreover, their REP 2139-Mg based combination therapy is poised to revolutionize the treatment of chronic HBV and HDV infections and aligns with the WHO's goal of eliminating viral hepatitis by 2030. With 292 million people suffering from chronic hepatitis B, Replicor's work could potentially have a significant global impact.

Business keywords: clinical-stage company, hepatitis B, HBV treatment, antiviral therapy, NAP technology, chronic infection, liver disease, clinical data, viral hepatitis, drug development, nucleic acid-based polymers, immune control, viral infections, innovative treatment

No funding data available for Replicor Inc. yet.

Replicor Inc. Alternatives & Competitors

View All Alternatives
Replicor Inc. vs
Idenix Pharmaceuticals
Idenix Pharmaceuticals

Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a stron...

Post-IPO Equity
Biotechnology, Health Care
Replicor Inc. vs
Antiva Biosciences, Inc.
Antiva Biosciences, Inc. United States

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical the...

Series E
30 employees
Biotechnology, Health Care
Compare Replicor Inc. vs Antiva Biosciences, Inc.
Replicor Inc. vs
Chromis Therapeutics
Chromis Therapeutics United States

Chromis Therapeutics, Inc. is a San Diego-based biopharmaceutical company, focused on the developmen...

Seed
51-200 employees
Biotechnology, Health Care
View all alternatives

FAQ About Replicor Inc.

292 million people have chronic hepatitis B. We're developing the cure.
Replicor Inc. is headquartered in Montreal, Canada.
Replicor Inc. operates in Biotechnology and Health Care. Its work centres on clinical-stage company, hepatitis B, HBV treatment and antiviral therapy.
Replicor Inc. has approximately 6 employees.
Top alternatives and competitors to Replicor Inc. include Idenix Pharmaceuticals, Antiva Biosciences, Inc., Chromis Therapeutics, Anadys Pharmaceuticals, Tolerx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Replicor Inc. and Idenix Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Replicor Inc., https://bouncewatch.com/company/replicor-inc, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout